TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00837941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: A: Pregabalin
Description: 1 Pregabalin 300 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: A: Pregabalin
Description: 1 Pregabalin 300 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: A: Pregabalin
Description: 1 Pregabalin 300 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: A: Pregabalin
Description: 1 Pregabalin 300 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: A: Pregabalin
Description: 1 Pregabalin 300 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: A: Pregabalin
Description: 1 Pregabalin 300 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: B: Duloxetine
Description: 1 Duloxetine hydrochloride 60 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: B: Duloxetine
Description: 1 Duloxetine hydrochloride 60 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: B: Duloxetine
Description: 1 Duloxetine hydrochloride 60 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: B: Duloxetine
Description: 1 Duloxetine hydrochloride 60 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: B: Duloxetine
Description: 1 Duloxetine hydrochloride 60 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: B: Duloxetine
Description: 1 Duloxetine hydrochloride 60 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: C: Diphenhydramine hydrochloride
Description: 1 Diphenhydramine hydrochloride 25mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: C: Diphenhydramine hydrochloride
Description: 1 Diphenhydramine hydrochloride 25mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: C: Diphenhydramine hydrochloride
Description: 1 Diphenhydramine hydrochloride 25mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: C: Diphenhydramine hydrochloride
Description: 1 Diphenhydramine hydrochloride 25mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: C: Diphenhydramine hydrochloride
Description: 1 Diphenhydramine hydrochloride 25mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: C: Diphenhydramine hydrochloride
Description: 1 Diphenhydramine hydrochloride 25mg capsule
Study: NCT03506711

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Handgrip Exercise during magnetic resonance imaging
Description: Coronary endothelial function are assessed by MRI with imaging studies done at baseline (at rest) and during IHE (under stress). Maximum grip strength is determined using an MRI-compatible dynamometer (Grip Force Fiber Optic Response Pad, Current Designs Inc., Philadelphia, USA) prior to baseline imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Handgrip Exercise during magnetic resonance imaging
Description: Coronary endothelial function are assessed by MRI with imaging studies done at baseline (at rest) and during IHE (under stress). Maximum grip strength is determined using an MRI-compatible dynamometer (Grip Force Fiber Optic Response Pad, Current Designs Inc., Philadelphia, USA) prior to baseline imaging.
Study: NCT02234479

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hydrophor (Group A)
Description: * Rehydrates dry, chapped or chafed skin~* May be used alone as a skin lubricant or protectant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MediHoney (Group B)
Description: It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~* Maintain a balanced environment for healing.~* Aids in reducing dermatitis.~* Reduce affected area pH.2-3
Study: NCT03118232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate (CHG)
Description: 2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodophor (10% povidone-iodine)
Description: Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
Study: NCT04169750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergames
Description: The training protocol will be delivered by the Nintendo ® Wii balance board and consists of repetitions of several games selected from the Wii Fit Plus package (http:// www.wiifit.com/training/balance-games.html). Each game starts at basic level, and when a certain score is reached, patients is automatically transferred to a more advanced level. Patients will be encouraged to play the next game if they have a level progress; otherwise, 10 minutes will be allocated for each game. During the first 4 weeks of training, patients will be allowed to play only Zazen (sitting position), Table Tilt and Ski Slalom; thereafter they will add the remaining games Penguin Slide, Tightrope Walk, Balance Bubble and Soccer Heading.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive COGNI-TRAcK
Description: The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet). The app implements three different types of exercises (each one executed for about 10 min a session), consisting in a visuo-spatial working memory task, an operation N-back task and a dual N-back task.~The adaptive training is structured so that the exercises difficulty level will increase by one step every time the user will perform a correct exercise. On the other hand, the difficulty level will decrease by one step if the exercise is incorrect for three times in a row.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham COGNI-TRAcK
Description: The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet) as previously described for adaptive COGNI-TRAcK. However, the non-adaptive training (placebo-analogue intervention) consists in an algorithm implementing two low difficulty levels alternating every day regardless of the user's performance.
Study: NCT04292808

Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyflurane
Description: Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.
Study: NCT03089593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extract of ginger
Description: The volunteers will receive two capsules containing 200mg of extract of ginger with 5% of gingerols (20 mg). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cellulose)
Description: The volunteers will receive two capsules containing cellulose (placebo). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
Study: NCT03351751

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: PF-06372865
Study: NCT02634151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo tablets administered orally once daily for 12 weeks.
Study: NCT01737918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Study: NCT03129087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal rest versus vocalization
Description: A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal rest versus vocalization
Description: A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
Study: NCT02724254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP611074 5% gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AP611074 matching placebo
Study: NCT00975299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-4367
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-4367
Description: Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
Study: NCT03380455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Single oral dose of 500 mg lucerastat under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: Twice daily oral dose of 800 mg cimetidine under fasted conditions
Study: NCT01523496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D control dose
Description: 18,000 IU per month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D control dose
Description: 18,000 IU per month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation-
Description: 60,000 IU per month(medium dose) or 120,000 IU/month(high dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation-
Description: 60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
Study: NCT04345289

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent anti-SARS-CoV-2 plasma
Description: Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infusion placebo
Description: Saline 0.9% (600 ml) as an iv single dose infusion
Study: NCT03807349

Intervention type: DEVICE
Group type: OTHER
Intervention: N-Force Screws Augmented with N-Force Blue
Description: N-Force Fixation System 7.3 mm (Non-fenestrated/fenestrated) applied with washers; N-Force Blue (Bone Substitute Material)
Study: NCT02799407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ResearchKit Consent
Description: Multi-tiered consent form using the Apple ResearchKit Platform.
Study: NCT00823628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: contrast agent (iopromide)
Description: coronary angiography using the allocated contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: contrast agent (iodixanol)
Description: coronary angiography using the allocated contrast agent
Study: NCT00351013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria Tropica Nosode D200
Description: 5 pellets every four months
Study: NCT05427409

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-alanine supplementation
Description: In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beta-alanine supplementation
Description: In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period
Study: NCT03549156

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C-RUSF
Description: -RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HIPRO RUSF
Description: HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
Study: NCT02506595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERRT-M for Nightmares
Description: Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
Study: NCT01397370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study: NCT02170883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive SMS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT01534247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAZ-AVI + metronidazole
Description: Infusion
Study: NCT02146508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR)
Description: Endoscopic removal of regions of ESD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Endoscopic radiofrequency ablation of regions of ESD
Study: NCT02997527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraluminal Impedance
Description: Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
Study: NCT02771704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver Diamine fluoride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium iodide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride and potassium iodide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological saline
Study: NCT05244759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BLU-5937
Description: Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.
Study: NCT04282395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience-Based Diabetes Self-Management Education
Description: During the group sessions led by professional nurses, participants are provided information and group activities to enable them to more effectively manage their personal diabetes challenges. During the support group sessions, participants discuss personal challenges and solutions to diabetes self-management, using a more informal approach. Booster sessions are held to refresh participants' understanding of how resilience resources can sustain self-management behaviors and maintain improved T2DM health outcomes. The RB-DSME also incorporates cultural characteristics and preferences of African Americans (AAs), to include:~* the location in community-based church settings,~* recognition of cultural dietary preferences, and~* emphasis on cultural/historical significance of resilience in AAs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Self-Management Education
Description: Control group sessions, led by professional nurses, cover topics such as:~* causes and symptoms of type 2 diabetes,~* glucose self-monitoring,~* models for and principles of healthy eating, grocery shopping and dining out,~* physical activity,~* diabetes medications,~* managing sick days and stress, and~* community resources.
Study: NCT02877368

Intervention type: OTHER
Intervention: Computed tomography
Study: NCT04172714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres microspheres
Description: SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.
Study: NCT03203044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soylent and water diet
Description: A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
Study: NCT02456844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
Description: 1. Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~2. Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~3. Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~4. Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~5. Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~6. BMS-986142: On Days 6 through 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate, Leucovorin and BMS-986142
Description: 1. Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~2. Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~3. BMS-986142 on Days 6 through 10.
Study: NCT01439321

Intervention type: BIOLOGICAL
Intervention: Eltrombopag
Description: Switched to Eltrombopag

Intervention type: BIOLOGICAL
Intervention: Romiplostim
Description: Switched to Romiplostim
Study: NCT03144245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMV564
Description: AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AMV564 in combination with pembrolizumab
Description: AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
Study: NCT01388660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloas
Description: A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I \& II Day 1 (crossover manner)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix/Astrix
Description: Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I \& II Day 1 (crossover manner)
Study: NCT02572726

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active repeated transcranial magnetic stimulation
Description: ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 'sham' repeated transcranial magnetic stimulation
Description: ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
Study: NCT02859181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Amino acid intakes will be varied at 0.2-2.67 g/kg/d
Study: NCT02571296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micronized progesterone
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT01534104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative fMRI. DTI and DSI with tractography
Description: W/I approx 4-6 weeks of the fMRI, DTI \& DSI, neurological/physical testing \& brain MRI showing tumor \&/or edema located in or near (\<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), \&/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately \<48 hours before surgery\*) fMRI to localize gray matter DTI, DSI \& tractography to localize white matter, DSI \& updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray \&/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (\<48 hours after surgery)
Study: NCT02970604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Non enteric coated aspirin
Study: NCT02808000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIP Foley (latex) or BIP Foley -silicone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP Foley (latex) or BIP Foley -silicone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard catheter
Study: NCT03735927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spot monitoring device, excl. Sham
Description: During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
Study: NCT00665899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer-Focused Relationship Enhancement
Description: Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple's Cancer Education
Description: Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
Study: NCT02242084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenuse Alteplase
Study: NCT00676676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone atch delivering 300mcg daily for 8-weeks
Study: NCT03753646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactating allowance and psycho social stimulation
Description: Mothers will receive lactating allowance and psycho social stimulation
Study: NCT02316535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: adjuvant chemotherapy;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: adjuvant chemotherapy;